Rhythm’s geneType Test to Reach Hundreds of Thousands via Know Your Lemons App

Strategic Partnership to Expand Reach

Rhythm Biosciences Ltd (ASX – RHY), an Australian medical diagnostics innovator, has announced a significant co-marketing partnership with the Know Your Lemons Foundation (KYL), a global non-profit dedicated to breast cancer education and early detection. This formal agreement marks a new chapter in Rhythm’s commercialisation strategy for its geneType Breast Cancer Risk Assessment Test, aiming to broaden its reach to hundreds of thousands of women across the United States and Australia.

Previously, KYL had engaged with Genetic Technologies Limited for access to geneType, but Rhythm has now taken stewardship of the relationship, signalling a more focused and collaborative approach. The partnership will leverage KYL’s extensive community and digital platforms, including their popular mobile application, to promote geneType through educational content such as blogs and webinars.

Aligning with Breast Cancer Awareness Month

The timing of this partnership is strategic, coinciding with Breast Cancer Awareness Month in October. This global health campaign provides an ideal platform to raise awareness about the importance of early detection and proactive breast health management. Rhythm and KYL plan to use this period to amplify messaging around geneType, encouraging women to consider genetic risk assessment as a complement to traditional screening methods.

Know Your Lemons has a remarkable global footprint, reaching over 2 billion people online and delivering in-person education in more than 75 countries. Their network of over 1,300 trained educators, known as “Lemonistas,” empowers women with knowledge about breast health, risk factors, and screening options. Integrating geneType into KYL’s offerings adds a sophisticated genetic risk assessment tool to their educational arsenal.

Implications for Rhythm Biosciences

For Rhythm Biosciences, this partnership represents a major milestone in elevating the geneType brand and accelerating its commercialisation. CEO David Atkins highlighted the potential impact, noting that activating geneType through KYL’s app could reach millions of women, supporting more informed and proactive health decisions. This aligns with Rhythm’s broader mission to improve early cancer detection and patient outcomes through innovative diagnostics.

GeneType’s platform combines clinical, family history, and genetic data to provide personalized risk assessments for breast cancer and other diseases, positioning it well within the growing preventative healthcare and precision medicine markets. The collaboration with KYL not only enhances visibility but also reinforces geneType’s role as a complementary tool alongside existing breast cancer screening pathways.

Looking Ahead

While the announcement does not disclose financial terms or specific revenue projections, the partnership’s scale and timing suggest a meaningful commercial opportunity. The success of this initiative will depend on user engagement, conversion rates, and the broader acceptance of genetic risk assessment in routine breast health management. Investors and stakeholders will be watching closely as Rhythm Biosciences leverages this collaboration to drive growth and impact in cancer diagnostics.